Sakar Healthcare Limited Stock

Equities

SAKAR

INE732S01012

Pharmaceuticals

Market Closed - NSE India S.E. 07:43:49 2024-04-26 am EDT 5-day change 1st Jan Change
355.4 INR +0.28% Intraday chart for Sakar Healthcare Limited -1.59% -11.15%
Sales 2022 1.29B 15.49M Sales 2023 1.34B 16.1M Capitalization 3.82B 45.82M
Net income 2022 152M 1.82M Net income 2023 128M 1.54M EV / Sales 2022 2.46 x
Net Debt 2022 857M 10.28M Net Debt 2023 1.16B 13.88M EV / Sales 2023 3.71 x
P/E ratio 2022
15.2 x
P/E ratio 2023
29.2 x
Employees 297
Yield 2022 *
-
Yield 2023
-
Free-Float 99%
More Fundamentals * Assessed data
Dynamic Chart
Sakar Healthcare Ltd Receives EU GMP Approval Dated 5th March 2024With A Validity of Three Years from Audited Date CI
Sakar Healthcare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Sakar Healthcare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Sakar Healthcare Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Sakar Healthcare Limited announced that it expects to receive INR 599.999123 million in funding from Tata Investment Corporation Limited CI
Sakar Healthcare Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Sakar Healthcare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Sakar Healthcare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Indian shares seen opening lower; U.S. jobs data in focus RE
Sakar Healthcare Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Sakar Healthcare Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022 CI
Sakar Healthcare Limited Reports Earnings Results for the Full Year Ended March 31, 2022 CI
Sakar Healthcare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
Sakar Healthcare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021 CI
Sakar Healthcare's Fully-Integrated Anti-Cancer Formulation Unit, Now Starting with Research Laboratories CI
More news
1 day+0.28%
1 week-1.59%
Current month-3.49%
1 month-2.80%
3 months-19.09%
6 months+5.29%
Current year-11.15%
More quotes
1 week
347.65
Extreme 347.65
371.40
1 month
347.65
Extreme 347.65
385.00
Current year
329.00
Extreme 329
479.00
1 year
210.00
Extreme 210
479.00
3 years
103.35
Extreme 103.35
479.00
5 years
44.00
Extreme 44
479.00
10 years
44.00
Extreme 44
479.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 33 12-05-31
Chief Executive Officer 64 04-03-25
Director of Finance/CFO 58 21-10-30
Members of the board TitleAgeSince
Director/Board Member 71 20-09-27
Director/Board Member 63 15-03-31
Founder 59 04-03-25
More insiders
Date Price Change Volume
24-04-26 355.4 +0.28% 9 234
24-04-25 354.4 -3.84% 34,181
24-04-24 368.6 +2.42% 14,204
24-04-23 359.9 +0.45% 11,618
24-04-22 358.3 -0.01% 14,577

Delayed Quote NSE India S.E., April 26, 2024 at 07:43 am EDT

More quotes
Sakar Healthcare Limited is an India-based company, which is engaged in the manufacturing of pharmaceutical products. The Company is engaged in providing liquid orals, cephalosporin tablets, capsules, dry powder syrup, dry powder injections, liquid injectables (SVP) in ampoules, vials and lyophilized injections, oral solid dosages, and research and development of these products. The Company’s products include Oral - Liquid Syrup & Suspension, Liquid Injectable (SVP)-Vials & Ampoules, Cephalosporin - Dry Powder Injections, Cephalosporin - Oral Solid and Lyophilised Injections (In Vials). The Company operates as a contract development and manufacturing organization (CDMO). The Company has approximately 321 product registrations in various countries. The manufacturing unit has been accredited by regulatory authorities of 14 countries, which includes Uganda, Kenya, Yemen, Ethiopia, Congo, Zimbabwe, Nigeria, Malawi, Philippines, Peru, Vietnam, Cote D’Ivoire.
More about the company